US 10082496
Targeting emopamil binding protein (EBP) with small molecules that induce an abnormal feedback response by lowering endogenous cholesterol biosynthesis
granted A61KA61K31/454A61K31/4545
Quick answer
US patent 10082496 (Targeting emopamil binding protein (EBP) with small molecules that induce an abnormal feedback response by lowering endogenous cholesterol biosynthesis) held by The Board of Regents of the University of Texas System expires Mon Sep 20 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The Board of Regents of the University of Texas System
- Grant date
- Tue Sep 25 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Sep 20 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 19
- CPC classes
- A61K, A61K31/454, A61K31/4545, A61K31/4725, A61K31/496